Your AI-Trained Oncology Knowledge Connection!
Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.
Luciano J. Costa, MD, PhD, discusses unmet needs in relapsed/refractory multiple myeloma.
Barry Paul Sleckman, MD, PhD, has been named director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
Cristina Magi-Galluzzi, MD, PhD, discusses the importance of properly diagnosing patients with prostate cancer to avoid overtreatment.
The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced.
Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Older patients with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure, according to results from an analysis of the SEER database.
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.
Sharon Spencer, MD, professor, chief of Medical Services, Ruby Meredith Outstanding Clinician Endowed Chair, University of Alabama at Birmingham School of Medicine, discusses the types of radiation therapy available to patients with head and neck cancer.